H. Lundbeck (HLUNBC) Stock Overview

Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details

HLUNBC fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	4/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 71.9% below our estimate of its fair value

Earnings have grown 20.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

HLUNBC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

H. Lundbeck A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for H. Lundbeck
Historical stock prices
Current Share Price	DKK 43.07
52 Week High	DKK 46.60
52 Week Low	DKK 34.24
Beta	0.38
1 Month Change	-7.02%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	63.64%
5 Year Change	n/a
Change since IPO	29.98%

Recent updates

Shareholder Returns

	HLUNBC	GB Pharmaceuticals	GB Market
7D	-2.1%	0.6%	2.3%
1Y	n/a	26.6%	16.4%

Return vs Industry: Insufficient data to determine how HLUNBC performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HLUNBC performed against the UK Market.

Price Volatility

Is HLUNBC's price volatile compared to industry and market?
HLUNBC volatility
HLUNBC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	5.0%
10% most volatile stocks in GB Market	10.7%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: HLUNBC's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine HLUNBC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,700	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
HLUNBC fundamental statistics
Market cap	DKK 42.16b
Earnings (TTM)	DKK 3.81b
Revenue (TTM)	DKK 24.08b

11.6x

P/E Ratio

1.8x

P/S Ratio

Is HLUNBC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLUNBC income statement (TTM)
Revenue	DKK 24.08b
Cost of Revenue	DKK 4.09b
Gross Profit	DKK 19.99b
Other Expenses	DKK 16.18b
Earnings	DKK 3.81b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 04, 2026

Earnings per share (EPS)	3.84
Gross Margin	83.01%
Net Profit Margin	15.82%
Debt/Equity Ratio	47.4%

How did HLUNBC perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

25%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/29 12:39
End of Day Share Price	2025/11/25 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 37 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Emily Field	Barclays
Rosie Turner	Barclays
Charles Pitman	Barclays

H. Lundbeck (HLUNBC) Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

Hikma Pharmaceuticals

HUTCHMED (China)

Haleon

GSK

Price History & Performance

Recent News & Updates

H. Lundbeck A/S Announces the Acceptance of Its New Drug Application

H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $ 2.1 billion.

H. Lundbeck A/S, Annual General Meeting, Mar 23, 2026

Lundbeck Announces its Bexicaserin Receives Breakthrough Therapy Designation in China for Treatment of Seizures in Severe Rare Epilepsies

Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD

H. Lundbeck A/S to Present New Data on Bexicaserin At Upcoming Congress

Recent updates

H. Lundbeck A/S Announces the Acceptance of Its New Drug Application

H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc (NasdaqGM:AVDL) for $ 2.1 billion.

H. Lundbeck A/S, Annual General Meeting, Mar 23, 2026

Lundbeck Announces its Bexicaserin Receives Breakthrough Therapy Designation in China for Treatment of Seizures in Severe Rare Epilepsies

Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD

H. Lundbeck A/S to Present New Data on Bexicaserin At Upcoming Congress

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck A/S Announces New Data from Phase III Trial Confirms Efficacy of Vyepti®? (eptinezumab) in Asian Population with Chronic Migraine

Lundbeck Advances Leadership in Migraine with New Data at American Headache Society 67th Annual Scientific Meeting

H. Lundbeck A/S Raises Earnings Guidance for the Full Year 2025

H. Lundbeck to Share Pipeline Data and Key Insights into the Progression of Rare Disease, Multiple System Atrophy, at International MSA Congress in Boston

H. Lundbeck A/S to Present Positive Pipeline Data At American Academy of Neurology Annual Meeting

H. Lundbeck A/S Expands the Dose Findings to Intravenous Administration of Lu AG09222 in Migraine Prevention

H. Lundbeck A/S Approves to Distribute Dividend for the Year 2024

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S (Lundbeck) Approves Rxulti®? (Brexpiprazole) for the Treatment of Schizophrenia

H. Lundbeck A/S Provides Earnings Guidance for the Year 2025

H. Lundbeck A/S, Annual General Meeting, Mar 26, 2025

H. Lundbeck A/S Announces Board Changes

H. Lundbeck A/S Announces Positive Results from 12-Month Open-Label Extension of the PACIFIC Trial Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

H. Lundbeck A/S (Lundbeck) Announces That the U.S. Food and Drug Administration Plans to Host A Psychopharmacologic Drugs Advisory Committee Meeting to Seek Input on Issues Related to the Supplemental New Drug Application for Brexpiprazole

H. Lundbeck A/S to Report First Half, 2025 Results on Aug 20, 2025

H. Lundbeck A/S Announces Positive Results from the Resolve Trial

H. Lundbeck Initiates a Phase III Trial with Amlenetug for the Treatment of Multiple System Atrophy

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Less than half of directors are independent

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S to Report Q1, 2023 Results on May 10, 2023